Whitehawk Therapeutics, Inc.: shareholders and insiders

WHWKNASDAQHealthcare · Pharmaceutical Preparations

Price

$3.07

November 20, 2026Market cap $288M

What Ploutos Investor adds for Whitehawk Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from 2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 22, 2025 to Sep 15, 2026, from their own Form 4 filings.

14 Form 4s

Bought on the market

–

nobody

Sold on the market

$2.6M

3 people

From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $2.6M by 3 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $2.6M by 3 people
  • May 14, 2026Anupam DalalDirector
    Kind
  • Apr 16, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICER
    Kind
  • Apr 15, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICER
    Kind
  • Apr 14, 2026Bryan Ball
    Kind
  • Apr 13, 2026Bryan Ball
    Kind
  • Apr 10, 2026Bryan Ball
    Kind
  • Apr 9, 2026Bryan Ball
    Kind
  • Apr 9, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind
  • Apr 8, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind
  • Apr 7, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind
  • Apr 6, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind
  • Apr 2, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind
  • Mar 2, 2026Scott M. GiacobelloCHIEF FINANCIAL OFFICER
    Kind
  • Mar 2, 2026Bryan Ball
    Kind
  • Mar 2, 2026David James LennonCHIEF EXECUTIVE OFFICER
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 15, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by WHWK's officers and directors from 2017 up to November 21, 2025, 9 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

7 Holders over 5%2 On a 13DAug 14, 2026 Latest filing
  • Avoro Capital Advisors LLCwith 2 more persons
    Share of class20.0%
  • Suvretta Capital Managementwith 2 more persons
    Share of class9.99%
  • ABG Management Ltd.with 12 more persons
    Share of class9.40%
  • QVT Financial LP
    Share of class9.37%
  • Acuta Capital Partnerswith 2 more persons
    Share of class9.00%
  • OrbiMed Advisors LLCwith 1 more person
    Share of class7.30%
  • Coastlands Capital LPwith 4 more persons
    Share of class5.98%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Avoro Capital Advisors LLC20.0%From the filing of May 14, 2026

    On May 12, 2026, the Issuer entered into a Securities Purchase Agreement (the "2026 Securities Purchase Agreement") with Avoro Life Sciences Fund LLC ("Avoro Life") and certain other purchasers named therein (collectively, the "2026 PIPE Investors"). Pursuant to the 2026 Securities Purchase Agreement, the Issuer agreed to sell to Avoro Life an aggregate of 6,377,714 pre-funded warrants (the "Pre-Funded Warrants") to acquire Common Stock at a purchase price of $3.9199 per share (the "2026 PIPE Financing"). The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable, and remain exercisable until exercised in full. Avoro Life may not…

    From the filing of May 14, 2026
  • Acuta Capital Partners9.0%From the filing of May 18, 2026

    The reporting persons are filing this Schedule 13D because Mr. Dalal is on the Issuer's board of directors. The reporting persons acquired the Stock for investment purposes based on their belief that the Common Stock, when purchased, was undervalued and represented an attractive investment opportunity. The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations, including, current and anticipated future trading prices of the Stock and other securities, the Issuer's operations, assets, prospects, financial position, and business development, Issuer's management, Issuer-related competitive and strategic matters,…

    From the filing of May 18, 2026
Fell to 5% or less (5)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Point72 Asset Management, L.P.0.00%May 15, 202513G/A
  • Neil Desai13D4.90%Mar 6, 202513D/A
  • BML Investment Partners, L.P.13D4.98%Mar 5, 202513D/A
  • Satter Muneer A0.00%Feb 14, 202513G/A
  • EcoR1 Capital, LLC1.40%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter-68%
  • Citadel Advisors (Griffin)
    In the quarter-50%
  • Millennium Mgmt (Englander)
    In the quarter+16%
  • Renaissance Technologies
    In the quarter+60%
  • AQR Capital
    In the quarter

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 2.79% of its shares outstanding were held short, -3.3% since the report before.

Shares held short
2.62M
2.79%
Since the report before2.71M on Sep 30, 2026
-3.3%
7.4
354.2K
More days to cover thanof 4,578 US-listed companies with enough volume
80%
Report date
Oct 15, 2026
  • Mar 31, 2025: Shares held short 1.17M
  • Apr 15, 2025: Shares held short 1.14M
  • Apr 30, 2025: Shares held short 213.8K
  • May 15, 2025: Shares held short 186.2K
  • May 30, 2025: Shares held short 173.3K
  • Jun 13, 2025: Shares held short 285.8K
  • Jun 30, 2025: Shares held short 618.3K
  • Jul 15, 2025: Shares held short 381.9K
  • Jul 31, 2025: Shares held short 362.1K
  • Aug 15, 2025: Shares held short 294.5K
  • Aug 29, 2025: Shares held short 242.7K
  • Sep 15, 2025: Shares held short 258.1K
  • Sep 30, 2025: Shares held short 233.0K
  • Oct 15, 2025: Shares held short 208.5K
  • Oct 31, 2025: Shares held short 1.03M
  • Nov 14, 2025: Shares held short 978.2K
  • Nov 28, 2025: Shares held short 649.2K
  • Dec 15, 2025: Shares held short 760.6K
  • Dec 31, 2025: Shares held short 735.6K
  • Jan 15, 2026: Shares held short 780.8K
  • Jan 30, 2026: Shares held short 847.4K
  • Feb 13, 2026: Shares held short 777.2K
  • Feb 27, 2026: Shares held short 780.9K
  • Mar 13, 2026: Shares held short 722.2K
  • Mar 31, 2026: Shares held short 693.9K
  • Apr 15, 2026: Shares held short 780.1K
  • Apr 30, 2026: Shares held short 824.7K
  • May 15, 2026: Shares held short 855.0K
  • May 29, 2026: Shares held short 843.7K
  • Jun 15, 2026: Shares held short 1.18M
  • Jun 30, 2026: Shares held short 2.83M
  • Jul 15, 2026: Shares held short 4.18M
  • Jul 31, 2026: Shares held short 4.43M
  • Aug 14, 2026: Shares held short 5.03M
  • Aug 31, 2026: Shares held short 2.98M
  • Sep 15, 2026: Shares held short 2.73M
  • Sep 30, 2026: Shares held short 2.71M
  • Oct 15, 2026: Shares held short 2.62M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading43.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 43.1% of the shares in the reported trades were short sales, against 52.3% in the 14 before.

Last 14 sessionsNov 3, 2026 – Nov 20, 2026
43.1%
The 14 beforeOct 14, 2026 – Nov 2, 2026
52.3%
Change
-9.2 pts
Short sales a dayon average, of 196.0K shares
84.5K
More than atof 3,666 US-listed companies, same days
27%
Median of alleight in ten from 34.4% to 63.9%
50.5%
  • Oct 14, 2026: Short sales 42.9%
  • Oct 15, 2026: Short sales 84.3%
  • Oct 16, 2026: Short sales 71.7%
  • Oct 19, 2026: Short sales 65.4%
  • Oct 20, 2026: Short sales 33.7%
  • Oct 21, 2026: Short sales 63%
  • Oct 22, 2026: Short sales 45.7%
  • Oct 23, 2026: Short sales 71.4%
  • Oct 26, 2026: Short sales 63.7%
  • Oct 27, 2026: Short sales 26.5%
  • Oct 28, 2026: Short sales 34.1%
  • Oct 29, 2026: Short sales 43.5%
  • Oct 30, 2026: Short sales 72.6%
  • Nov 2, 2026: Short sales 43.7%
  • Nov 3, 2026: Short sales 30.8%
  • Nov 4, 2026: Short sales 25.5%
  • Nov 5, 2026: Short sales 55.7%
  • Nov 6, 2026: Short sales 37%
  • Nov 9, 2026: Short sales 27.2%
  • Nov 10, 2026: Short sales 47.5%
  • Nov 11, 2026: Short sales 19.8%
  • Nov 12, 2026: Short sales 80.3%
  • Nov 13, 2026: Short sales 57.7%
  • Nov 16, 2026: Short sales 69.7%
  • Nov 17, 2026: Short sales 66.9%
  • Nov 18, 2026: Short sales 59%
  • Nov 19, 2026: Short sales 71.5%
  • Nov 20, 2026: Short sales 66.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

7.07M Insiders' shares14.98% Of the company
  • Anupam DalalDirector
    Directly4.69M
  • Neil DesaiEXECUTIVE CHAIRMAN
    Directly–
  • David James LennonCHIEF EXECUTIVE OFFICER
    Directly518.6K
  • Bryan BallSee remarks
    Directly397.1K
  • Scott M. GiacobelloCHIEF FINANCIAL OFFICER
    Directly295.2K

A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

3 ETFs holding it0.03% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.03%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.00%

3 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

78 Managers, Q2 2026$198M Value of their positions
  • Q3 2025: Managers 41
  • Q4 2025: Managers 48
  • Q1 2026: Managers 64
  • Q2 2026: Managers 78

Institutional investors by quarter

The fund managers holding WHWK, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 78 managers held 43.24M shares, worth $198M. During the quarter 28 opened a position, 15 closed one, 28 added and 10 trimmed.

The largest holders, Q2 2026

  • Yu Fan
    In the quarter+135%
  • Acuta Capital Partners
    In the quarter+37%
  • QVT Financial
    In the quarter
  • Montanova Capital
    In the quarter+16%
  • Orbimed Advisors
    In the quarter-5.6%
  • Avoro Capital Advisors
    In the quarter
  • Siren
    In the quarter+12%
  • KVP Capital Advisors
    In the quarter
  • BlackRock
    In the quarter+447%
  • Vanguard Capital Management
    In the quarter+5.5%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Whitehawk Therapeutics's filings show?

Who buys and sells is one part of Whitehawk Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about WHWK's shareholders

Didn't find what you were looking for?

Ask us
Have WHWK's insiders bought or sold?

From Jun 15, 2026 to Sep 15, 2026 Whitehawk Therapeutics's insiders reported no purchase or sale of shares on the market.

Which well-known managers hold WHWK?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $2.5M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.